125,807 Shares in Elanco Animal Health Incorporated (NYSE:ELAN) Purchased by Equitable Trust Co.

Equitable Trust Co. purchased a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 125,807 shares of the company’s stock, valued at approximately $1,524,000.

Several other hedge funds have also modified their holdings of the company. Geode Capital Management LLC increased its holdings in shares of Elanco Animal Health by 0.8% during the third quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock valued at $115,623,000 after acquiring an additional 65,303 shares in the last quarter. Atom Investors LP grew its stake in shares of Elanco Animal Health by 310.3% during the 3rd quarter. Atom Investors LP now owns 345,855 shares of the company’s stock worth $5,081,000 after purchasing an additional 261,559 shares during the period. Harbor Capital Advisors Inc. lifted its position in shares of Elanco Animal Health by 24.0% during the 4th quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company’s stock valued at $13,135,000 after buying an additional 209,734 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Elanco Animal Health by 19.2% during the 3rd quarter. Wellington Management Group LLP now owns 4,007,805 shares of the company’s stock valued at $58,875,000 after buying an additional 646,522 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in shares of Elanco Animal Health by 14.0% during the 3rd quarter. Franklin Resources Inc. now owns 372,230 shares of the company’s stock valued at $5,349,000 after buying an additional 45,795 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Down 0.5 %

NYSE ELAN opened at $11.47 on Tuesday. Elanco Animal Health Incorporated has a 52 week low of $11.11 and a 52 week high of $18.80. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The business’s fifty day simple moving average is $12.01 and its 200-day simple moving average is $13.19. The firm has a market cap of $5.67 billion, a PE ratio of 28.67, a P/E/G ratio of 2.69 and a beta of 1.42.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ELAN shares. Stifel Nicolaus decreased their price objective on Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Leerink Partners started coverage on Elanco Animal Health in a report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective on the stock. Barclays raised their price objective on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 8th. UBS Group started coverage on Elanco Animal Health in a report on Monday, December 9th. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, Morgan Stanley decreased their price objective on Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 29th. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $16.29.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.